MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-05-2026
Viemed Healthcare Cost of Revenue 2011-2026 | VMD
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Viemed Healthcare
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 M | 91.1 M | 70.2 M | 54.2 M | 43.7 M | 51.2 M | 24.2 M | 16.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 115 M | 16.7 M | 58.3 M |
Quarterly Cost of Revenue Viemed Healthcare
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 32.6 M | - | 30.6 M | 26.3 M | 25.8 M | - | 23.6 M | 22.1 M | 20.8 M | - | 18.8 M | 17.2 M | 15.6 M | - | 14.1 M | 12.9 M | 12.5 M | - | 10.9 M | 9.77 M | 10.7 M | - | 14 M | 16.9 M | 8.25 M | - | 6.32 M | 5.69 M | 5.04 M | 4.84 M | 4.1 M | 4.18 M | 3.56 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 32.6 M | 3.56 M | 14.5 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 4.13 | -0.72 % | $ 155 M |  France |
 |
Apyx Medical Corporation
APYX
|
19.8 M | $ 3.67 | 3.09 % | $ 151 M |  USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
232 M | $ 7.52 | -2.97 % | $ 1.13 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 2.22 | 3.26 % | $ 1.35 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 17.81 | 1.37 % | $ 418 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
LENSAR
LNSR
|
31.3 M | $ 5.64 | 7.84 % | $ 67.4 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 12.82 | 9.76 % | $ 363 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | -0.08 % | $ 38 M | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 71.86 | 1.32 % | $ 3.92 B |  Britain |
 |
Delcath Systems
DCTH
|
11.8 M | $ 11.48 | 2.14 % | $ 411 M | USA |
 |
Orthofix Medical
OFIX
|
256 M | $ 11.65 | -3.48 % | $ 461 M |  Curacao |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | - | $ 17.4 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
Myomo
MYO
|
14 M | $ 0.83 | -5.05 % | $ 34.7 M | USA |
 |
Electromed
ELMD
|
14 M | $ 26.93 | 0.26 % | $ 228 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 4.16 | -2.0 % | $ 881 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Profound Medical Corp.
PROF
|
4.7 M | $ 6.85 | -4.33 % | $ 207 M | Canada |
 |
Insulet Corporation
PODD
|
768 M | $ 154.16 | -3.89 % | $ 10.8 B | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.35 | -2.08 % | $ 6.52 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 77.95 | -8.37 % | $ 10.5 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 36.76 | -3.52 % | $ 1.14 B | USA |
 |
Stryker Corporation
SYK
|
9.05 B | $ 285.47 | -2.98 % | $ 109 B | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 44.26 | -2.87 % | $ 1.3 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.12 | 0.23 % | $ 3.06 B | USA |
 |
Invacare Corporation
IVC
|
566 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.33 B | $ 79.96 | -3.44 % | $ 46.8 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 15.48 | -16.19 % | $ 1.05 B | USA |